Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 328 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is P  [Clear All Filters]
2025
Kent A, Mon KJoy Yee, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI et al..  2025.  A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis.. Nat Immunol. 26(1):53-67.
Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D et al..  2025.  SuFEx-based antitubercular compound irreversibly inhibits Pks13.. Nature.
Mostert D, Braun J, Zimmerman MD, Engelhart CA, Berndl S, Quoika PK, Kany AM, Proietto J, Penalva-Lopez S, Wallach JB et al..  2025.  Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly.. Chem Sci. 16(21):9472-9483.
Mostert D, Braun J, Zimmerman MD, Engelhart CA, Berndl S, Quoika PK, Kany AM, Proietto J, Penalva-Lopez S, Wallach JB et al..  2025.  Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly.. Chem Sci. 16(21):9472-9483.
Schwer B, Prucker I, Sanchez AM, Babor J, Jessen HJ, Shuman S.  2025.  Tandem inactivation of inositol pyrophosphatases Asp1, Siw14, and Aps1 illuminates functional redundancies in inositol pyrophosphate catabolism in fission yeast.. mBio. 16(5):e0038925.
Singh A, Zwerneman LT, Planck K, Kaneko T, Perkowski AJ, Suh CM, Alex A, Bean J, Burns-Huang K, Zhang D et al..  2025.  Thioquinazolinones as Antituberculosis Agents Targeting Phosphopantetheinyl Transferase.. J Med Chem. 68(14):14645-14698.
Singh A, Zwerneman LT, Planck K, Kaneko T, Perkowski AJ, Suh CM, Alex A, Bean J, Burns-Huang K, Zhang D et al..  2025.  Thioquinazolinones as Antituberculosis Agents Targeting Phosphopantetheinyl Transferase.. J Med Chem. 68(14):14645-14698.
Itkin T, Houghton S, Schreiner R, Lin Y, Badwe CR, Voisin V, Murison A, Seyedhassantehrani N, Kaufmann KB, Garcia-Prat L et al..  2025.  Transcriptional activation of regenerative hematopoiesis via microenvironmental sensing.. Nat Immunol. 26(3):378-390.
2026
Hunt DM, Pisco JPedro, Rodgers A, de Chiara C, Zaveri A, Pacholarz KL, Evangelopoulos D, Garza-Garcia A, Ehrt S, Schnappinger D et al..  2026.  Activation of L-histidine biosynthesis as a new antibiotic strategy against Mycobacterium tuberculosis.. Nat Commun. 17(1)
Hunt DM, Pisco JPedro, Rodgers A, de Chiara C, Zaveri A, Pacholarz KL, Evangelopoulos D, Garza-Garcia A, Ehrt S, Schnappinger D et al..  2026.  Activation of L-histidine biosynthesis as a new antibiotic strategy against Mycobacterium tuberculosis.. Nat Commun. 17(1)
Tsai C-Y, Xie M, Cristaldo M, Peluso GR, Woo J, Nuritdinov F, Odjourian NM, Dougher M, Antilus-Sainte R, Kreutzfeldt KM et al..  2026.  BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice.. J Infect Dis.
Warrier T, Martinez-Hoyos M, de Francisco EPorras, Lenaerts AJ, Gruppo V, Robertson GT, Li K, Aubé J, Bonnet I, Jiang X et al..  2026.  Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.. ACS Infect Dis.
Babor J, Sanchez AM, Prucker I, Jessen HJ, Schwer B, Shuman S.  2026.  How interdiction of inositol pyrophosphate catabolism perturbs the fission yeast response to phosphate starvation.. Nucleic Acids Res. 54(8)
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Sanders RW, Caniels TG, Moore JP, Permar SR.  2026.  Learned young: HIV-1 germline-targeting vaccination in infants.. Curr Opin HIV AIDS.
Visone JE, Florini F, Hadjimichael E, Patel V, Deitsch KW.  2026.  Mechanistic insights into coordinated var transcriptional switching in malaria parasites.. EMBO J. 45(8):2614-2637.
Pinto AJ, Silva M, Santos JA, VanderVen BC, Monteiro R, Schnappinger D, Ehrt S, Beites T.  2026.  Mycobacterium tuberculosis long-chain fatty acid resistome reveals universal stress protein TB15.3 as essential for infection.. Commun Biol.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Valdambrini E, Kodadek T, Peel M, Barany F.  2026.  Overcoming limitations of targeted protein degraders: developments toward reversible, self-assembling degraders.. Future Med Chem. :1-3.
Prajapati SK, Dong JX, Morahan BJ, Dotrang T, Barbeau MC, Williams AE, Hupalo D, Wilkerson MD, Dalgard CL, Kafsack BFC et al..  2026.  A single valine to leucine switch disrupts Plasmodium falciparum AP2-G DNA binding and reveals GDV1's role in ap2-g activation.. Nat Commun.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.